Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Price Target at $16.88

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have earned an average recommendation of “Hold” from the six analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $16.8750.

Several research firms have commented on HCM. Jefferies Financial Group raised HUTCHMED to a “strong-buy” rating in a report on Monday, January 19th. Bank of America decreased their price objective on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. Weiss Ratings restated a “hold (c)” rating on shares of HUTCHMED in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th.

HUTCHMED Stock Down 4.7%

NASDAQ:HCM opened at $13.87 on Tuesday. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.05. HUTCHMED has a one year low of $12.98 and a one year high of $19.50. The company has a fifty day moving average price of $14.63 and a 200 day moving average price of $14.64.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings results on Friday, March 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.50 by ($2.49). The business had revenue of $135.42 million for the quarter, compared to the consensus estimate of $290.50 million. As a group, equities research analysts anticipate that HUTCHMED will post 0.41 EPS for the current year.

Hedge Funds Weigh In On HUTCHMED

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC increased its holdings in HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after purchasing an additional 124,771 shares in the last quarter. UBS Group AG grew its holdings in shares of HUTCHMED by 112.8% during the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after purchasing an additional 72,614 shares during the last quarter. Amundi increased its stake in shares of HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock valued at $3,620,000 after buying an additional 65,898 shares in the last quarter. M&G PLC increased its stake in shares of HUTCHMED by 26.7% in the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after buying an additional 54,601 shares in the last quarter. Finally, XY Capital Ltd raised its holdings in shares of HUTCHMED by 291.1% in the third quarter. XY Capital Ltd now owns 52,757 shares of the company’s stock valued at $831,000 after buying an additional 39,266 shares during the last quarter. 8.82% of the stock is owned by institutional investors.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.